US Post News
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
  • Home
  • Stocks Trading
  • Analyst Snapshot
  • Market Summary
  • Financial Scores
No Result
View All Result
US Post News
No Result
View All Result

The Future Is Here? Moderna Inc. (MRNA)

August 17, 2022
in Financial Scores

Moderna Inc. (NASDAQ: MRNA) has got permission from the UK authorities to launch a vaccine against new strains of COVID-19.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.

Sponsored

MRNA has acquired permission in the United Kingdom for a “next-generation COVID-19 vaccine,” as the firm describes it. This is a bivalent COVID-19 booster vaccination containing mRNA-1273.214. It should be noted that this is the first time that a bivalent vaccination tailored to tackle the omicron form has been licensed by authorities.

While the vaccine is licensed for anyone aged 18 and up, when additional safety data becomes available, the age range may be increased.

Spikevax from the original COVID-19 strain is combined with a novel chemical that targets the omicron BA.1 variation in the mRNA-1273.214 vaccine. A bivalent vaccination, according to Moderna Inc. (MRNA) management, would be better equipped to deal with the new viral type.

Positive Phase II/III clinical results back up Moderna’s claims. A booster dose of the bivalent vaccination was observed in studies to enhance neutralizing titers against omicron by around eight times from baseline. Furthermore, the vaccine demonstrated efficacy against novel omicron types, such as BA.4 and BA.5.

As a result, MRNA continues to profit from COVID-19 vaccinations. Despite the fact that the Omicron strain appears to be less hazardous than its predecessors, the epidemiological scenario indicates that the demand for coronavirus prevention will remain for some time.

Simultaneously, it is impossible to forecast how many vaccinations Moderna Inc. (MRNA) will be able to sell in practice. The corporation receives orders from governments all around the world, but vaccination demand is frequently lower than expected, forcing Moderna to burn massive numbers. Management disclosed a write-off of about $500 million in expired vaccinations in its second-quarter financial report.

Moderna Inc. (MRNA) has the benefit of currently executing various mRNA-based initiatives unrelated to COVID-19. This means that it will be able to profit from other efforts in the long term.

Moderna Inc. (NASDAQ: MRNA) stock has dropped -1.86% in the last week but is up 23.26% in the last quarter. Going back further, the stock’s price has increased by more than 17.89% in the previous six months but is down -33.87% year to date.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Silvergate Capital Corporation (NYSE:SI) stock crossing the finish line today

February 27, 2023

Is OrganiGram Holdings Inc. (OGI) a threat to investors?

March 23, 2023

Today’s watch list includes XPO Logistics Inc. (NYSE:XPO) stock

March 17, 2023

“US Post News” – one of the oldest and most authoritative news sites in America. It was established in 1992, journalists, photographers, correspondents, researchers came to the publication from the editorial offices of regional newspapers, drama theater, etc. They had no training, and they gained experience and skill in the process of work.

Contact us: ceo@www.uspostnews.com

Catagories

  • Market Summary
  • Stocks Trading
  • Analyst Snapshot
  • Financial Scores

Company

  • Home
  • About US
  • Contact US

RECENT POSTS

  • The Battle of Fundamentals and Techniques: Bloom Energy Corporation (BE)
  • There Are Mixed Signals on the Chart for Sea Limited (SE)
  • Introducing Our Rant Against SoFi Technologies Inc.

Copyright © 2022 US Post News

No Result
View All Result
  • About US
  • Contact US
  • Home

Copyright © 2022 US Post News